Trademark Overview
On Wednesday, January 26, 2022, a trademark application was filed for KAYLUNRIE with the United States Patent and Trademark Office. The USPTO has given the KAYLUNRIE trademark a serial number of 97240191. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, September 11, 2023. This trademark is owned by Eli Lilly and Company. The KAYLUNRIE trademark is filed in the Pharmaceutical Products category with the following description:
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases
